



Vicore offers advance voting in connection with the 2020 AGM

Gothenburg, May 4, 2020 – Vicore Pharma Holding AB (publ) hereby informs that the shareholders may exercise their voting rights at the Annual General Meeting 2020 by voting in advance. Vicore encourages all shareholders to use this option in order to minimise the number of participants attending the general meeting in person, as part of the effort to minimise the risk of spreading the coronavirus.

A special form shall be used for advance voting. The form is available on https://vicorepharma.com/wp-content/uploads/2020/04/vicore_pharma_-_agm_2020_-_formulr_fr_frhandsrstning_och_anmlan_eng.pdf

A shareholder who is exercising its voting right through advance voting do not need to notify the company of its attendance to the general meeting. The advance voting form is considered as the notification of attendance to the general meeting.

The completed voting form must be submitted to Vicore no later than Thursday 14 May 2020. The completed and signed form shall be sent to by e-mail to nina.carlen@vicorepharma.com, or by post to Vicore Pharma Holding AB (publ), attn. Nina Carlén, Kronhusgatan 11, SE-411 05 Göteborg, Sweden. If the shareholder is a legal entity, a certificate of incorporation or a corresponding document shall be enclosed to the form. The same apply for shareholders voting in advance by proxy. The shareholder may not provide special instructions or conditions in the voting form. If so, the vote is invalid.

Further instructions and conditions are included in the form for advance voting.

For information about the Annual General Meeting 2020 visit:

<https://vicorepharma.com/investors/corporate-governance/general-meeting/>

For further information, please contact:

Carl-Johan Dalsgaard, CEO, tel: +46 70 975 98 63, carl-johan.dalsgaard@vicorepharma.com

About Vicore Pharma Holding AB (publ)

Vicore Pharma is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has two drug development programs, VP01 and VP02.

VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”) and pulmonary fibrosis in systemic sclerosis (“SSc”). VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.